Brought to you by 
Dey licenses Chiesi's Curosurf
21 Apr 2015
Executive Summary
Dey Laboratories, a unit of Merck KGaA's Merck Generics Group, has licensed the the exclusive US and Canadian rights to Chiesi Farmaceutici's Curosurf, a lung surfactant for infants with respiratory distress syndrome.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dey licenses Chiesi's Curosurf
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice